Giasemi C. Eptaminitaki

Mrs. Giasemi C. Eptaminitaki

Medical School, University of Crete, Heraklion, Greece
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in Drug Resistance Updates
Verified
Journal Article
Closed access
GEGiasemi C. Eptaminitaki
Giasemi C. Eptaminitaki
DSDimitrios Stellas
Dimitrios Stellas
BBBenjamin Bonavida
Benjamin Bonavida
SBStavroula Baritaki
Stavroula Baritaki

26 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
GEGiasemi C. Eptaminitaki
Giasemi C. Eptaminitaki
NWNora Wolff
Nora Wolff
DSDimitrios Stellas
Dimitrios Stellas
KSKonstantinos Sifakis
Konstantinos Sifakis
SBStavroula Baritaki
Stavroula Baritaki
Long non-coding RNAs (lncRNAs) are critical regulatory elements in cellular functions in states of both normalcy and disease, including cancer. LncRNAs can influence not only tumorigenesis but also cancer features such as metastasis, angiogenesis and resistance to chemo-and immune-mediated apoptotic signals. Several lncRNAs have been demonstrated to control directly or indirectly the number, type and activities of distinct immune cell populations of adaptive and innate immunities within and without the tumor microenvironment. The disruption of lncRNA expression in both cancer and immune cells may reflect alterations in tumor responses to cancer immunosurveillance and immunotherapy, thus providing new insights into lncRNA biomarker-based prognostic and therapeutic cancer assessment. Here we present an overview on lncRNAs’ functions and underlying molecular mechanisms related to cancer immunity and conventional immunotherapy, with the expectation that any elucidations may lead to a better understanding and management of cancer immune escape and response to current and future immunotherapeutics.

4 May 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MCMeng Cui
Meng Cui
KXKEMAN XU
KEMAN XU
KGKirin D. Gada
Kirin D. Gada
BSBoris Shalomov
Boris Shalomov
MBMichelle Ban
Michelle Ban
Diomedes Elias LogothetisDiomedes Elias Logothetis
Diomedes Elias Logothetis
G protein–sensitive inwardly rectifying potassium (GIRK) channels are important pharmaceutical targets for neuronal, cardiac, and endocrine diseases. Although a number of GIRK channel modulators have been discovered in recent years, most lack selectivity. GIRK channels function as either homomeric (i.e., GIRK2 and GIRK4) or heteromeric (e.g., GIRK1/2, GIRK1/4, and GIRK2/3) tetramers. Activators, such as ML297, ivermectin, and GAT1508, have been shown to activate heteromeric GIRK1/2 channels better than GIRK1/4 channels with varying degrees of selectivity but not homomeric GIRK2 and GIRK4 channels. In addition, VU0529331 was discovered as the first homomeric GIRK channel activator, but it shows weak selectivity for GIRK2 over GIRK4 (or G4) homomeric channels. Here, we report the first highly selective small-molecule activator targeting GIRK4 homomeric channels, 3hi2one-G4 (3-[2-(3,4-dimethoxyphenyl)-2-oxoethyl]-3-hydroxy-1-(1-naphthylmethyl)-1,3-dihydro-2H-indol-2-one). We show that 3hi2one-G4 does not activate GIRK2, GIRK1/2, or GIRK1/4 channels. Using molecular modeling, mutagenesis, and electrophysiology, we analyzed the binding site of 3hi2one-G4 formed by the transmembrane 1, transmembrane 2, and slide helix regions of the GIRK4 channel, near the phosphatidylinositol-4,5-bisphosphate binding site, and show that it causes channel activation by strengthening channel–phosphatidylinositol-4,5-bisphosphate interactions. We also identify slide helix residue L77 in GIRK4, corresponding to residue I82 in GIRK2, as a major determinant of isoform-specific selectivity. We propose that 3hi2one-G4 could serve as a useful pharmaceutical probe in studying GIRK4 channel function and may also be pursued in drug optimization studies to tackle GIRK4-related diseases such as primary aldosteronism and late-onset obesity.

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MCMeng Cui
Meng Cui
YAYaser Alhamshari
Yaser Alhamshari
LCLucas Cantwell
Lucas Cantwell
SESaid Ei-Haou
Said Ei-Haou
GEGiasemi C. Eptaminitaki
Giasemi C. Eptaminitaki
Diomedes Elias LogothetisDiomedes Elias Logothetis
Diomedes Elias Logothetis
Atrial fibrillation (AF) is the most commonly diagnosed cardiac arrhythmia and is associated with increased morbidity and mortality. Currently approved AF antiarrhythmic drugs have limited efficacy and/or carry the risk of ventricular pro-arrhythmia. The cardiac acetylcholine activated inwardly rectifying K+ current (IKACh), composed of Kir3.1/Kir3.4 heterotetrameric and Kir3.4 homotetrameric channel subunits, is one of the best validated atrial-specific ion channels. Previous research pointed to a series of benzopyran derivatives with potential for treatment of arrhythmias, but their mechanism of action was not defined. Here, we characterize one of these compounds termed Benzopyran-G1 (BP-G1), and report that it selectively inhibits the Kir3.1 (GIRK1 or G1) subunit of the KACh channel. Homology modeling, molecular docking, and Molecular Dynamics simulations predicted that BP-G1 inhibits the IKACh channel by blocking the central cavity pore. We identified the unique F137 residue of Kir3.1 as the critical determinant for the IKACh-selective response to BP-G1. The compound interacts with Kir3.1 residues E141 and D173 through hydrogen bonds that proved critical for its inhibitory activity. BP-G1 effectively blocked the IKACh channel response to carbachol in an in vivo rodent model, and displayed good selectivity and pharmacokinetic properties. Thus, BP-G1 is a potent and selective small molecule inhibitor targeting Kir3.1-containing channels and is a useful tool for investigating the role of Kir3.1 heteromeric channels in vivo. The mechanism reported here could provide the molecular basis for future discovery of novel, selective IKACh channel blockers to treat atrial fibrillation with minimal side effects.

7 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
GEGiasemi C. Eptaminitaki
Giasemi C. Eptaminitaki
Apostolos ZaravinosApostolos Zaravinos
Apostolos Zaravinos
DSDimitrios Stellas
Dimitrios Stellas
Maria PanagopoulouMaria Panagopoulou
Maria Panagopoulou
SKSevasti Karaliota
Sevasti Karaliota
SBStavroula Baritaki
Stavroula Baritaki
Pancreatic ductal adenocarcinoma (PDAC), the second most prevalent gastrointestinal malignancy and the most common type of pancreatic cancer is linked with poor prognosis and, eventually, with high mortality rates. Early detection is seldom, while tumor heterogeneity and microarchitectural alterations benefit PDAC resistance to conventional therapeutics. Although emerging evidence suggest the core role of cancer stem cells (CSCs) in PDAC aggressiveness, unique stem signatures are poorly available, thus limiting the efforts of anti-CSC-targeted therapy. Herein, we report the findings of the first genome-wide analyses of mRNA/lncRNA transcriptome profiling and co-expression networks in PDAC cell line-derived CD133+/CD44+ cells, which were shown to bear a CSC-like phenotype in vitro and in vivo. Compared to CD133−/CD44− cells, the CD133+/CD44+ population demonstrated significant expression differences in both transcript pools. Using emerging bioinformatic tools, we performed lncRNA target coding gene prediction analysis, which revealed significant Gene Ontology (GO), pathway, and network enrichments in many dyregulated lncRNA nearby (cis or trans) mRNAs, with reported involvement in the regulation of CSC phenotype and functions. In this context, the construction of lncRNA/mRNA networks by ingenuity platforms identified the lncRNAs ATF2, CHEK1, DCAF8, and PAX8 to interact with “hub” SC-associated mRNAs. In addition, the expressions of the above lncRNAs retrieved by TCGA-normalized RNAseq gene expression data of PAAD were significantly correlated with clinicopathological features of PDAC, including tumor grade and stage, nodal metastasis, and overall survival. Overall, our findings shed light on the identification of CSC-specific lncRNA signatures with potential prognostic and therapeutic significance in PDAC.

19 October 2025 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Open access
ESEvagelia Skouradaki
Evagelia Skouradaki
GEGiasemi C. Eptaminitaki
Giasemi C. Eptaminitaki
EKEvagelia Kirio
Evagelia Kirio
AZApostolos Zaravinos
Apostolos Zaravinos
NDNikolas Dovrolis
Nikolas Dovrolis
SBStavroula Baritaki
Stavroula Baritaki
Raf-1 Kinase Inhibitor Protein (RKIP) is a well-known metastasis suppressor that regulates key oncogenic signaling pathways. Emerging evidence also points to a dual role for RKIP as an immunomodulatory molecule, influencing the tumor immune microenvironment, a complex niche that promotes immune evasion and overall tumor progression. This review explores RKIP's impact on immune surveillance via its interactions with signaling pathways and cellular components of the tumor microenvironment, as well as its role in recruiting and polarizing immune cells with different dynamics in reshaping an immunocompetent milieu. We further discuss how RKIP downregulation promotes immune evasion, alters cytokine profiles, and reduces effector immune cell infiltration. Current studies suggest that RKIP supports type I interferon signaling and antigen presentation, while its loss contributes to an immunosuppressive, pro-metastatic environment. Therefore, by regulating the expression of RKIP in the pathways that control TME architecture, the TME can be reprogramed towards an immunoprotected milieu. Altogether, this review underscores RKIP's role in tumor immunity, offering new perspectives for therapeutic strategies aimed at overcoming cancer immune evasion and improving immunotherapy efficacy.